180 related articles for article (PubMed ID: 2503471)
1. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil.
Fujii S; Fukushima M; Shimamoto Y; Shirasaka T
Jpn J Cancer Res; 1989 Jun; 80(6):509-12. PubMed ID: 2503471
[TBL] [Abstract][Full Text] [Related]
2. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcomas in rats.
Fujii S; Shimamoto Y; Ohshimo H; Imaoka T; Motoyama M; Fukushima M; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):167-72. PubMed ID: 2498251
[TBL] [Abstract][Full Text] [Related]
3. [BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Fujii S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2244-50. PubMed ID: 2955745
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Fujii S; Fukushima M; Shimamoto Y; Ohshimo H; Imaoka T; Shirasaka T
Jpn J Cancer Res; 1989 Feb; 80(2):173-81. PubMed ID: 2498252
[TBL] [Abstract][Full Text] [Related]
5. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
8. 3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.
Tatsumi K; Yamauchi T; Kiyono K; Kishi K; Yanagihara Y; Imaoka T; Kawaguchi T; Kubo M
J Biochem; 1993 Dec; 114(6):912-8. PubMed ID: 8138551
[TBL] [Abstract][Full Text] [Related]
9. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors.
Adjei AA; Reid JM; Diasio RB; Sloan JA; Smith DA; Rubin J; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Atherton P; Ames MM; Erlichman C
J Clin Oncol; 2002 Mar; 20(6):1683-91. PubMed ID: 11896120
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
[TBL] [Abstract][Full Text] [Related]
12. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation.
Rustum YM
Oncology; 1997; 54 Suppl 1():7-11. PubMed ID: 8978578
[TBL] [Abstract][Full Text] [Related]
15. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T
Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829
[TBL] [Abstract][Full Text] [Related]
16. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT].
Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S
Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014
[TBL] [Abstract][Full Text] [Related]
17. Effect of coadministration of thymine or thymidine on the antitumor activity of 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil.
Fujii S; Kitano S; Ikenaka K; Fukushima M; Nakamura H; Maehara Y; Shirasaka T
Gan; 1980 Feb; 71(1):100-6. PubMed ID: 6769735
[TBL] [Abstract][Full Text] [Related]
18. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
19. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
[TBL] [Abstract][Full Text] [Related]
20. [Regulation of enzyme activities involved in pyrimidine synthesis and its application to cancer chemotherapy].
Shirasaka T; Fujii S
Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):760-8. PubMed ID: 6424581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
